✉ Email this page to a colleague
« Back to Dashboard
Arbaclofen is an investigational drug.
There have been 29 clinical trials for Arbaclofen. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2011.
The most common disease conditions in clinical trials are Autism Spectrum Disorder, Multiple Sclerosis, and Child Development Disorders, Pervasive. The leading clinical trial sponsors are Seaside Therapeutics, Inc., Indivior Inc., and Osmotica Pharmaceutical US LLC.
Recent Clinical Trials for Arbaclofen
|A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis||RVL Pharmaceuticals, Inc.||Phase 3|
|Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion||Clinical Research Associates, LLC||Phase 2|
|Arbaclofen in Children and Adolescents With ASD||Hospital General Universitario Gregorio Marañon||Phase 2|